Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden- Analysis Using 28-Month Overall Survival from Checkmate 067
Oct 1, 2017, 00:00
10.1016/j.jval.2017.08.261
https://www.valueinhealthjournal.com/article/S1098-3015(17)30595-8/fulltext
Title :
Cost-Effectiveness of Nivolumab in Combination with Ipilimumab in First-Line Treatment of Advanced Melanoma in Sweden- Analysis Using 28-Month Overall Survival from Checkmate 067
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(17)30595-8&doi=10.1016/j.jval.2017.08.261
First page :
A444
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
239